Skip to main content
. Author manuscript; available in PMC: 2018 Feb 2.
Published in final edited form as: Mol Pharm. 2017 Aug 31;14(10):3248–3257. doi: 10.1021/acs.molpharmaceut.7b00231

Figure 3.

Figure 3

IN delivery of compound 1 to nonhuman primates resulted in 1:1 CSF/plasma ratio of 2-PMPA. (A) Time course of 2-PMPA delivery to plasma after IN administration of compound 1 to nonhuman primate shows that the prodrug resulted in delivery of high nM concentrations of 2-PMPA and significant systemic exposure. (B) At 30 min post dose, compound 1 achieved CSF delivery of high nM 2-PMPA, resulting in a CSF/plasma ratio of near unity, indicative of favorable distribution into the CNS. Data are presented as mean ± SEM (n = 3) for plasma and as mean for CSF (n = 2).